Cyadox
is a novel derivative of quinoxaline-1,4-dioxides (QdNOs)
with the potential to be developed as a feed additive. However, the
pharmacological and toxicological bioactive molecules of cyadox and
the molecular mechanism of its pharmacological and toxic actions remain
unclear. In the present study, cyadox and its main metabolites of
cy1, cy4, cy6, and cy12 were selected; the growth promotion characteristic
was indicated by the mRNA level of EGF; and the cytotoxicity of cyadox
was determined by methylthiazol tetrazolium bromide (MTT) assay, lactate
dehydrogenase (LDH) release, and Annexin V-FITC/PI apoptosis detection
kit with flow cytometry. The intracellular ROS, cyclin D1, and Akt/P53/FOXO1
signaling pathway were also investigated. Our data suggested that
cyadox showed relatively higher activity than its metabolites, and
the ROS was generated from N–O reduction of cyadox. Moreover,
cyadox (2 μM) activated the Akt and increased the EGF, cyclin
D1, and FOXO1 expression levels. Cyadox (100 μM) induced cytotoxicity
in L02 cells in a concentration- and time-dependent manner. Additionally,
the activated P53 pathway, hyperactivated Akt, and apoptosis were
found in L02 cells after incubation with 100 μM cyadox. Our
data demonstrated that Akt promoted cell survival when it was mildly
activated by cyadox at 2 μM, and Akt leads to apoptosis when
it was severely activated by cyadox at 100 μM. Thus, the present
study revealed that N–O reduction of cyadox and ROS-mediated
AKT/FOXO1 and AKT/P53 pathways were involved in growth promotion and
cytotoxicity of cyadox.